Question 1

What is HUTCHMED?

Accepted Answer

HUTCHMED is a Company.

Question 2

How often does HUTCHMED appear in global news?

Accepted Answer

Tracked across 2 news events drawn from 12 articles.

Question 3

When was HUTCHMED first tracked by Ergen?

Accepted Answer

First tracked on Apr 09, 2026.

Question 4

When was HUTCHMED last mentioned in news?

Accepted Answer

Last active on Jul 02, 2026.

Question 5

What is HUTCHMED's current news sentiment?

Accepted Answer

Aggregate sentiment score: 78 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is HUTCHMED in global news coverage?

Accepted Answer

Attention score of 6, derived from article volume and coverage intensity across 2 events.

Question 7

What is the most recent event involving HUTCHMED?

Accepted Answer

HUTCHMED Fanregratinib Phase II Results (Jun 24, 2026, 6 articles).

Question 8

How did the "HUTCHMED Fanregratinib Phase II Results" event impact HUTCHMED?

Accepted Answer

HUTCHMED announced positive results from its pivotal Phase II study of fanregratinib for intrahepatic cholangiocarcinoma, which is a significant milestone for the company's drug development pipeline and could lead to regulatory approval and commercialization.

Question 9

How did the "ORPATHYS Approved for Gastric Cancer in China" event impact HUTCHMED?

Accepted Answer

HUTCHMED, a biopharmaceutical company, received conditional approval from the China — National Medical Products Administration for its drug ORPATHYS (savolitinib) for gastric cancer treatment in China. This marks the third approved indication for ORPATHYS in China and validates HUTCHMED's R&D platform.

Question 10

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.